An evaluation of butoconazole nitrate 2% site release vaginal cream (Gynazole-1) compared to fluconazole 150 mg tablets (Diflucan) in the time to relief of symptoms in patients with vulvovaginal candidiasis. by Seidman, Larry S & Skokos, Campbell K
CLINICAL STUDY
An evaluation of butoconazole nitrate 2% Site Release
 vaginal cream
(Gynazole-1
) compared to ﬂuconazole 150 mg tablets (Diﬂucan
)
in the time to relief of symptoms in patients with vulvovaginal
candidiasis
LARRY S. SEIDMAN
1 & CAMPBELL K. SKOKOS
2
1Philadelphia Women’s Research, Philadelphia, PA, USA, and
2The Women’s Clinic, Little Rock, Arizona, AR, USA
(Received 15 July 2004; accepted 18 April 2005)
Abstract
Background. It is estimated that as many as 13 million cases of vulvovaginal infection occur in the United States annually,
the majority of which are the result of Candida albicans infection. The symptoms of vulvovaginal infections are often painful
and distressing to the patient. The objective of this study was to compare the time to symptomatic relief of vulvovaginal
candidiasis (VVC) with butoconazole nitrate 2% Site Release
1 vaginal cream (Gynazole-1
1) and oral ﬂuconazole 150 mg
tablets (Diﬂucan
1).
Methods. This randomized, open-label, parallel study evaluated 181 female patients with moderate to severe symptoms of
VVC. Patients were randomized to single-dose therapy with either butoconazole nitrate 2% Site Release
1 vaginal cream or
ﬂuconazole. The primary outcome measure was the time to onset of ﬁrst relief of symptoms. Secondary measures included
the time to overall relief of symptoms and the reinfection rate over the ﬁrst 30 days following treatment. The overall safety of
both products was investigated through the collection of adverse event reports.
Results. The median time to ﬁrst relief of symptoms occurred at 17.5 h for butoconazole patients as compared to 22.9 h for
ﬂuconazole patients (p50.001). The time at which 75% of patients experienced ﬁrst relief of symptoms was 24.5 h versus
46.3 h for butoconazole and ﬂuconazole, respectively (p50.001). By 12- and 24-h post-treatment, 44.4% and 72.8% of
patients in the butoconazole treatment group reported ﬁrst relief of symptoms versus 29.1% and 55.7% of patients in the
ﬂuconazole group (p=0.044 and p=0.024 respectively). In patients experiencing ﬁrst relief of symptoms within 48 h of
dosing, the median time to ﬁrst relief of symptoms in the butoconazole treatment group was signiﬁcantly shorter at 12.9 h
compared to 20.7 h for the ﬂuconazole treatment group (p=0.048). There were no signiﬁcant differences between the two
groups with respect to time to total relief of symptoms or reoccurrence of infection within 30 days of treatment.
Butoconazole therapy was shown to have fewer reported adverse events, including drug-related adverse events, than
ﬂuconazole therapy. Vulvovaginal pruritis and vulvovaginal burning were the most common drug-related adverse events
attributed to butoconazole. Headache, diarrhea, nausea, upset stomach and skin sensitivity were the most common drug-
related adverse events attributable to ﬂuconazole.
Conclusions. Single-dose butoconazole nitrate 2% Site Release
1 vaginal cream provides statistically signiﬁcant
improvement in time to ﬁrst relief of symptoms in the treatment of VVC compared to ﬂuconazole. There is no difference
between these two treatments with respect to total relief of symptoms or reinfection rate. Although there was no signiﬁcant
difference in the incidence of adverse events judged by the investigator to be treatment-related, butoconazole treatment did
result in fewer patients experiencing adverse events than ﬂuconazole.
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Introduction
Vulvovaginal infections are one of the most fre-
quently diagnosed vaginal infections in the United
States with approximately 13 million cases occurring
per year [1]. Nearly all vulvovaginal infections are
caused by the yeast Candida spp., with over 80% of
all infections due to Candida albicans [2]. It has been
estimated that 75% of all females will experience at
least one episode of vulvovaginal candidiasis (VVC)
with approximately 40% to 50% reporting a reoccur-
rence during their lifetime [3]. Although 25% to 40%
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who do develop symptoms these are often painful
and uncomfortable and can include intense itching,
irritation, vaginal discharge and dysuria [1–3].
The most commonly prescribed treatment for
VVC infection in recent years has been the imidazole
antifungals. These come in a number of different
formulations including single, three and seven day
cream applications, vaginal suppositories and oral
tablets. These imidazole antifungals are available
either by prescription or over-the-counter. While all
of these products are effective when taken according
to the approved dosage regimen, poor compliance,
ease of use and side effect proﬁle can prevent suc-
cessful therapy in as many as 50% of women treating
VVC infection [4]. In order to improve patient
compliance, signiﬁcant research and development
has focused on developing single-dose imidazole
formulations that are easy to use, effective and bring
early relief for the signs and symptoms of VVC to the
patient [5].
Currently four single-dose therapies are available in
the United States. These include an over-the-counter
vaginal ointment and cream containing 6.5% tioco-
nazole (multiple manufacturers), an over-the-counter
vaginal ovule containing 1200 mg of miconazole
nitrate (Monistat-1
1, McNeil-PPC, NJ), a prescrip-
tion-only butoconazole nitrate 2% single application
vaginal cream (Gynazole-1
1, Ther-Rx Corporation,
St Louis) and prescription-only ﬂuconazole 150 mg
oral tablets (Diﬂucan
1, Pﬁzer Inc, NY).
Gynazole-1
1 was developed with vagisite, a
patented Site Release
1 technology. It is a single-
dose, bioadhesive, butoconazole nitrate 2% Site
Release
1 vaginal cream that is available in a pre-
ﬁlled, single-use applicator. The objective of devel-
oping this product was to provide patients with a
single-dose topical formulation that was simple to
use and would improve treatment compliance.
Clinical studies demonstrated that this single-use
formulation has a median vaginal retention time of
4.2 days compared with 2.57 days for the standard
2% cream [6]. Gynazole-1
1 was approved for
marketing by the Food and Drug Administration
(FDA) of the United States in 1999.
Fluconazole (Diﬂucan
1) is the only orally avail-
able imidazole with approved labeling speciﬁc for the
treatment of VVC. The recommended dosing regi-
men is a single 150 mg oral tablet. Several clinical
studies have compared a single ﬂuconazole 150 mg
oral tablet with a number of different antifungal
vaginal topical and vaginal suppository preparations.
Review of these studies suggests that the overall cure
rate with ﬂuconazole 150 mg tablets is similar to that
seen with other preparations [7–15].
As the symptoms of VVC are often painful and
uncomfortable to the patient, time to ﬁrst relief and
time to total relief of symptoms should be an
important factor for both the patient and caregiver
to consider when deciding on a suitable therapy for a
particular patient. The objective of this study was to
compare the time to relief of symptoms due to
moderate to severe VVC, using either butoconazole
nitrate 2% Site Release
1 vaginal cream single-dose
or ﬂuconazole single-dose 150 mg oral tablets.
Materials and methods
Study design
This clinical trial was an open-label, randomized,
parallel design study conducted at thirteen research
facilities across the United States. Prior to initiation
of the study, the protocol and informed consent were
reviewed and approved by an independent Institu-
tional Review Board. The study was conducted from
May to November 2003.
Study population
To be eligible for participation, study patients had to
meet the following inclusion criteria: female, aged
18 years or older, not pregnant as determined by
urine pregnancy test and, if of child-bearing poten-
tial, willing to use a reliable method of contraception
during the duration of the study. Patients veriﬁed
understanding of the requirements of the study and
willingness to participate by signing the informed
consent form.
Conﬁrmation of current vulvovaginal candidiasis
(VVC) infection was made by use of KOH wet mount
preparation, pelvic examination and patient’s report-
ing of signs and symptoms. As the primary study
endpoint was time to ﬁrst relief of symptoms and not
therapeutic efﬁcacy, yeast cultures to conﬁrm the
KOH wet mount were not performed. Each patient
was required to indicate the overall severity of major
symptoms (itching,burning, irritation, etc.)onascale
from 0 (no symptoms) to 10 (severe symptoms). A
total severityscoreof54was requiredforinclusionin
the study. Other than VVC infection, patients had to
beingeneralgoodhealth, freeofanyotherconcurrent
vaginal infection, and, in the opinion of the investiga-
tors, therapy with either butoconazole or ﬂuconazole
waswarranted.Patientswhohadahistoryofrecurrent
VVC, as deﬁned as more than four episodes in the
previous 12 months, or were suspected of having a
concurrent vaginal infection such as bacterial vagino-
sis,trichomoniasisorherpeticlesionswerenoteligible
for participation. Patients who were menstruating, or
anticipated they would start menstruating within two
days of study drug dosing, were also excluded from
the study. Any patient who had used any intravaginal
or systemic antifungal medication within the previous
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as a spermicide, medicated douche or feminine spray
within two days was also excluded. Current treatment
for any medical condition that included systemic
antimycotics, corticosteroids or immunosuppressive
drugs also resulted in exclusion. In addition, a patient
was not eligible if she had a medical history of
hypersensitivity to any of the active or inactive
ingredients of either of the study drugs or similar
products, was taking any concurrent medication that
wascontraindicatedwitheitherofthetestproducts,or
in the investigator’s opinion was not suitable for
inclusion in the study. None of the patients enrolled
could have participated in a previous research study
within the last 30 days and were only eligible to
participate on one occasion.
A total of 181 patients were enrolled into the
study.
Treatments
Using a computer-generated randomization that was
prepared prior to the study, patients who met the
inclusion/exclusion criteria were allocated to one of
two treatment groups. Patients in group A received a
single application of approximately 5 g of butocona-
zole nitrate 2% Site Release
1 vaginal cream
(Gynazole-1
1, Ther-Rx Corporation). Patients ran-
domized to group B received one ﬂuconazole 150 mg
tablet (Diﬂucan
1, Pﬁzer). Patients were required to
take the medication at the investigator’s ofﬁce and the
time of dosing was recorded. Whenever possible,
patients were dosed before noon, although some
subjects received their doses in the early afternoon.
Following dosing, each patient was provided with
a patient diary in which they were requested to
record the date and time they ﬁrst started to feel
relief of symptoms, and the date and time they had
complete relief of symptoms. Patient evaluated
symptoms included vaginal itching, burning, and
irritation. Patients were also requested to record any
adverse events or concomitant medications.
Follow-up visits
Five to ten days following dosing, patients were
required to return to the investigator’s ofﬁce for a
follow-up visit. During this visit, the patient diary
was checked for completion and the patient was
questioned about any adverse events or concomitant
medications.
Approximately 30 days after dosing, a telephone
call was made to the patient to investigate whether
she had required additional treatment for her yeast
infection. If she had previously claimed that the
initial VVC infection had been resolved, she was
asked whether she had experienced a reinfection.
Statistical analysis
Baseline demographics (age, race, number of epi-
sodes of VVC in the previous 12 months and severity
score) were tabulated and compared using descrip-
tive statistics. Time to ﬁrst relief of symptoms and
time to total relief of symptoms for each individual
patient were calculated using the dosing time and the
time reported for each by the patient. Analysis of this
data was performed using Kaplan–Meier estimates
and 95% Conﬁdence Interval analysis. Adverse event
reports were coded into standardized MedDRA
version 6.1 terminology and tabulated by treatment
and event.
Statistical tests of superiority of butoconazole
compared to ﬂuconazole were two-sided and con-
ducted at a 5% level of signiﬁcance. p Values of less
than 0.05 were considered statistically signiﬁcant. All
eligible patients who reported a date or time to ﬁrst
relief or total relief were included in the correspond-
ing analysis. All patients who received study drug
were included in the safety analysis.
Based upon exponential distributions of time to
event, it was determined a priori that 150 patients
(approximately 75 per treatment group) would pro-
vide 80% power to detect at least a 20% difference in
superiority of butoconazole compared to ﬂuconazole
for time to ﬁrst relief of symptoms.
Results
A total of 181 women were randomized to the study,
with 93 assigned to butoconazole treatment and 88
assigned to ﬂuconazole treatment. A total of 160
patients (81 in the butoconazole treatment group and
79 in the ﬂuconazole treatment group) were eligible
forinclusionintheanalysisoftimetoﬁrstrelief.Atotal
of 136 patients (67 for butoconazole and 69 for
ﬂuconazole) were eligible for analysis of time to total
relief, and all 181 patients were included in the safety
analysis. Twenty-one patients (12 butoconazole pa-
tients and nine ﬂuconazole patients) were excluded
from the time to ﬁrst relief analysis, 18 of which were
duetomissingdata.Forty-ﬁvesubjectswereexcluded
from the time to total relief analysis (26butoconazole-
treated patients and 19 ﬂuconazole-treated patients),
41 of which were due to missing data.
Baseline demographics were similar between the
two groups. The mean age+standard deviation
(SD) was 38.8+13.8 years for the butoconazole
group and 37.0+12.2 years for the ﬂuconazole
treatment group. The mean number of vaginal yeast
infections in the previous year was 0.8 and 0.9 for
butoconazole and ﬂuconazole groups respectively.
The mean baseline severity score+SD for butoco-
nazole was 6.9+1.7 and 6.8+1.9 for ﬂuconazole.
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reported hours to ﬁrst symptom relief, a higher
percentage of patients treated with butoconazole
experienced ﬁrst relief of symptoms at all time points
compared to ﬂuconazole. Fifty percent of patients
receiving butoconazole experienced ﬁrst relief of
symptoms within 17.5 h versus 22.9 h with ﬂucona-
zole. The cumulative distribution of the time to ﬁrst
symptom relief was statistically signiﬁcant between
butoconazole and ﬂuconazole (p=0.006). Within
24.5 h, 75% of butoconazole-treated patients experi-
enced ﬁrst relief of symptoms. In contrast, only
55.7% of ﬂuconazole patients had ﬁrst relief of
symptoms within 24 h and it took nearly two full
days, 46.3 h, for 75% of ﬂuconazole patients to
exhibit ﬁrst relief of symptoms, an approximate
difference of 21.8 h (95% CI of the difference 21.7,
21.9, p50.001).
Over the ﬁrst 48 h, the time to ﬁrst relief of
symptoms was consistently shorter with butocona-
zole therapy, reaching statistical signiﬁcance between
the two therapies as early as 2 h post-treatment
(Table I). The percentage of patients exhibiting ﬁrst
relief of symptoms at 12 h was 44.4% for butocona-
zole and 29.1% for ﬂuconazole (p=0.044). Within
the ﬁrst 48 h post-treatment, 91.4% of butocona-
zole-treated patients experienced ﬁrst relief of
symptoms compared to 81% for patients treated
with ﬂuconazole.
Throughout the study, the time to complete relief
of symptoms was similar between the two treatment
regimens (p=0.182), as seen in Figure 2. The
median time for total relief was 64.0 h for butoco-
nazole treatment and 73.5 h for ﬂuconazole
treatment. Within 72 h of study treatment, 97.5%
of butoconazole-treated patients experienced some
relief of symptoms and 58.2% achieved complete
relief. Similarly, 93.7% of patients treated with
ﬂuconazole experienced some relief at 72 h and
47.8% achieved complete relief. Among patients
evaluable for complete relief, a total of nine patients
(13.4%) treated with butoconazole and 13 patients
(18.8%) treated with ﬂuconazole experienced a
reoccurrence of VVC within 30 days of study
treatment.
Overall, 66 adverse events occurred in the
butoconazole treatment group and 99 adverse events
in the ﬂuconazole treatment group. Among these
events, 16 and 32 were considered drug-related in
the corresponding treatment groups. The most
commonly reported adverse events are listed in
Table II. Adverse events considered to be drug-
related were reported by 11.8% of butoconazole-
treated patients compared to 20.5% of patients
treated with ﬂuconazole (p=0.114). The most
common drug-related adverse events reported for
both treatments are listed in Table III. For butoco-
nazole-treated patients, the most common drug-
related adverse events included vulvovaginal pruritis
and vulvovaginal burning. The most common drug-
related adverse events attributed to ﬂuconazole
therapy were headache, diarrhea, nausea, skin
sensitivity and upset stomach.
Discussion
Both butoconazole and ﬂuconazole offer clinicians
an effective regimen for the treatment of VVC with
the added beneﬁt of being a single-dose regimen,
designed to increase patient compliance over multi-
ple-dose therapies [5,9–11]. The goal of single-dose
therapy is to increase patient compliance without
sacriﬁcing time to onset of relief of the symptoms of
VVC. This study has shown that topical therapy
exhibits a more rapid onset to relief of symptoms of
VVC versus systemic therapy.
For this study, the overall time to complete relief
of symptoms when treated with an oral versus a
topical therapy, are consistent with those reported in
the literature [5,7–11,16]. Similarly, the time to ﬁrst
relief of symptoms for patients treated with ﬂucona-
zole in this study is similar to the results reported in
studies of similar design using ﬂuconazole. In a study
comparing oral ﬂuconazole with terconazole vaginal
cream, Seidman et al. [17] reported that the median
time to initial relief with ﬂuconazole was 21.3 h. This
correlates well with the 22.9 h seen in this study.
In the current study, for patients experiencing ﬁrst
relief of symptoms within 48 h, the time to onset of
symptom relief was shorter with butoconazole
therapy when compared to ﬂuconazole therapy
(12.9 h versus 20.7 h, p=0.048). Overall, within
12 h of dosing, approximating when the majority of
study patients may be preparing for bedtime, almost
half of the women treated with butoconazole
experienced ﬁrst relief of their symptoms. With
ﬂuconazole therapy, within this same 12 h period,
approximately one third of the study patients had
experienced ﬁrst relief of symptoms. From a clinical
perspective, 24 h is a reasonable period of time for
purposes of gauging general effectiveness of therapy
for VVC. For butoconazole-treated patients, 72.8%
experienced ﬁrst symptom relief at one day versus
55.7% for ﬂuconazole (p=0.024). Consequently,
this data may serve to support a clinician who
informs patients treated for VVC that symptom
relief may take longer with oral ﬂuconazole than
with topical butoconazole vaginal cream. Interest-
ingly, in a survey conducted on women in 1992 with
VVC, 71% reported that ‘fast relief’ of symptoms
was the most important aspect of treating a yeast
infection [18]. Treating with topical therapy more
directly addresses and impacts this overwhelming
patient priority.
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1 vaginal cream 201Patients enrolled in this study were encouraged to
dose study drugs in the morning where possible to
prevent ﬁrst relief of symptoms occurring during
sleeping hours. It was determined that no subjects in
thisstudyreportedﬁrstreliefofsymptomsbetweenthe
hoursof12:30 amto5:30 am,thereforeasub-analysis
was conducted to investigate the possible effect that
time spent in sleep may have on reported relief of
symptoms.Butoconazole-treatedsubjectsdosedprior
to 11:00 am experienced ﬁrst relief of symptoms the
same day (median 11.5 h). Whereas those butocona-
zole-treated subjects dosed after 11:00 am had a
median time to ﬁrst relief of symptoms of 19.6 h. For
ﬂuconazole-treated patients, the median time to ﬁrst
relief of symptoms was 29.6 h at or before 11:00 am
and 21.5 h after 11:00 am. These results should not
beinterpretedthatdosing intheafternoon delaystime
to onset of relief, rather patients who are asleep may
not realize a decrease in symptoms until they awaken.
Themediantimeofdosinginthisstudywas11:50 am
for butoconazole-treated patients and 11:30 am for
ﬂuconazole-treated patients. Therefore, the reported
time to ﬁrst relief of symptoms of 17.5 h for
butoconazole-treated patients may reﬂect a delay for
the time these subjects spent in slumber (Figure 3).
The overall objective of any therapy for the
treatment of vaginal candidiasis is the eradication
of the infecting organism and the absence of any
signs and symptoms. A limitation in the current
study is the absence of deﬁnitive data on the true
rates of cure based upon follow-up mycological
examination. This study, however, was designed to
identify the time to ﬁrst relief of the symptoms of
VVC following therapy with either a single-dose oral
or a single-dose vaginal regimen. As a result, the time
to total relief of symptoms and apparent reinfection
rate are used as general markers of the absence of the
infecting organism. The rates of time to total relief
and rates of reinfection were not statistically different
between the two study medications.
In addition, the time to relief of symptoms and
reinfection rates in this study support other pub-
lished data that butoconazole is at least as efﬁcacious
in microbiological cure as other topically approved
therapies [5,19,20]. The microbiological activity of
butoconazole tested favorably against four other
commonly used azole antifungals in an in vitro
susceptibility study by Lynch and Sobel [19]. The
authors reported consistently high levels of antifun-
gal activity and comparatively lower MICs for
Table I. Cumulative percentage of patients with first relief of symptoms following dosing by treatment group.
Butoconazole group Fluconazole group p value
Hours after dosing Cumulative % (N=81) Cumulative % (N=79) (*statistically significant)
2 12.3 2.5 0.018*
4 25.9 11.4 0.019*
6 32.1 17.7 0.036*
8 37.0 22.8 0.049*
10 42.0 27.8 0.061
12 44.4 29.1 0.044*
14 48.1 31.6 0.033*
16 48.1 31.6 0.033*
18 50.6 31.6 0.015*
20 55.6 36.7 0.017*
22 61.7 48.1 0.083
24 72.8 55.7 0.024*
26 76.5 57.0 0.009*
28 77.8 58.2 0.008*
30 80.2 62.0 0.011*
32 81.5 67.1 0.037*
34 82.7 67.1 0.022*
36 84.0 68.4 0.020*
38 84.0 68.4 0.020*
40 84.0 68.4 0.020*
42 84.0 68.4 0.020*
44 86.4 72.2 0.026*
46 90.1 74.7 0.010*
48 91.4 81.0 0.057
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204 L. S. Seidman & C. K. Skokosbutoconazole against C. albicans, C. glabrata, C.
parapsilosis, C. tropicalis, S. cerevisiae, C. lusitaniae, C.
krusei, C. kefyr, and C. stellatoidea. In a separate
portion of this same study, ﬂuconazole similarly
showed excellent activity against C. albicans, but
appeared to be far less active against the other species
listed above, particularly C. glabrata and S. cerevisiae.
While in vitro susceptibility testing cannot always
predict in vivo activity or clinical success, it does offer
a valuable tool for the clinician in evaluating and
understanding the spectrum of activity of both
butoconazole and ﬂuconazole against pathogens
commonly encountered in clinical practice.
Although this study was not powered to compare
the incidence of adverse events between treatment
groups, fewer patients in the butoconazole-treated
group reported drug-related adverse events than
patients treated with ﬂuconazole. However this
difference did not reach statistical signiﬁcance, as
there was an insufﬁcient number of reported drug-
related adverse events to reach any conclusions about
statistical signiﬁcance. A larger trial, designed to
evaluate drug-related adverse events, may be war-
ranted to further investigate this ﬁnding. The
reduced incidence of adverse events reported for
butoconazole, whether or not drug-related, may be
an indication of improved tolerability to a topical
therapy for a topical infection such as VVC. In
addition to an increased potential for adverse events,
systemic therapy for a local infection poses an
increased risk for drug interactions. According to
the Diﬂucan
1 prescribing information, drug inter-
actions have been reported with cimetidine,
rifampin, warfarin, phenytoin, cyclosporine, zidovu-
dine, theophylline, oral hypoglycemics, rifabutin,
tacrolimus and cisapride [21]. The Gynazole-1
1
prescribing information indicates that there are no
known drug interactions, however, issues related to
product leakage and vaginal irritation upon admin-
istration may be encountered. The difference in
patients reporting adverse events with butoconazole
therapy versus ﬂuconazole therapy, in addition to the
increased potential for drug interactions with oral
therapy, merits further investigation.
Conclusion
This study demonstrates that a single application of
butoconazole 2% vaginal bioadhesive cream more
rapidly achieves ﬁrst relief of the signs and symptoms
of vaginal candidiasis compared to ﬂuconazole
150 mg oral tablets. Almost half, 44.4%, of patients
using butoconazole nitrate 2% Site Release
1 vaginal
cream obtained ﬁrst relief of their symptoms within
12 h of application compared to 29% for ﬂucona-
zole. Three quarters of patients treated with buto-
conazole experienced ﬁrst relief of symptoms within
24.5 h versus 46.3 h for ﬂuconazole-treated patients.
Butoconazole nitrate 2% Site Release
1 vaginal
cream addresses an important patient preference,
speed of symptom relief, and should be considered as
an important ﬁrst line therapy in patients presenting
with the signs and symptoms of vaginal candidiasis.
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